NOVARTIS for NOVARTIS
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Access to Life Saving Medicines Act Provide Medicare Part B Coverage for Vaccines Covered under Part D Medicaid Coverage of Vaccines Medicare Prescription Drugs and Modernization Act Immunosuppressant Legislation
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| MARY L COEN | — |
| DAVID DRAKE | — |
| JAMES ELKIN | — |
| SARAH HALLER | — |
| BRENDA J LUCKRITZ | — |
| SHAWN O'NEAIL | — |
| KATHERINE SOLON | — |
| JENNIFER YOUNG MALONEY | — |
Taxation/Internal Revenue Code TAX
Orphan Drug Tax Credit
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| MARY L COEN | — |
| DAVID DRAKE | — |
| JAMES ELKIN | — |
| SARAH HALLER | — |
| BRENDA J LUCKRITZ | — |
| SHAWN O'NEAIL | — |
| KATHERINE SOLON | — |
| JENNIFER YOUNG MALONEY New | — |
Animals ANI
HR 1406 Fairness to Pet Owners Act of 2011 S 1211/HR 965 Preservation of Antibiotics for Medical Treatment Act of 2011 Animal Drug User Fee Re-authorization (ADUFA)
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENDA J LUCKRITZ | — |
Trade (domestic/foreign) TRD
Free Trade Agreements: - Intellectual Property Provisions in Panama, Colombia, Korea Access to Medicines Global Health Issues/Global Pandemic Influenza Planning Trans-Pacific Partnership FTA Sub-standards Medicines Quality of Medicines
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| MARY L COEN | — |
| DAVID DRAKE | — |
| JAMES ELKIN | — |
| SARAH HALLER | — |
| BRENDA J LUCKRITZ | — |
| SHAWN O'NEAIL | — |
| KATHERINE SOLON | — |
| JENNIFER YOUNG MALONEY | — |
Health Issues HCR
HR 452 - Medicare Decisions Accountability Act of 2011 S 319 - Pharmaceutical Market Access and Drug Safety Act of 2011 Gene Therapy Personalized Medicine H.R.2245 Preserving Access to Life-Saving Medications Act of 2011 S.296 Preserving Access to Life-Saving Medications Act S.1206 Medicare Drug Savings Act of 2011 H.R.2190 Medicare Drug Savings Act of 2011 Section 9008 of Patient Protection and Affordable Care Act Prescription Drug User Fee Act (PDUFA) S 75 - Generics First Act 2009 HR 276 - Proper Disposal of Unused Pharmaceuticals HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes 21st Century Cancer Bill Public Health Service Act Dextromethorphan - Age Restrictions - Controlling bulk shipments Pseudoephedrine - Promote e-tracking; oppose Rx legislation FSA/HSA - Support reinstating coverage of OTC products Enhance supply and shipping parameters for beta-Propiolactone HR 2182, S 1734 Support incentives for development of new, innovative antibiotics (former GAIN Act) MDUFA (Medical Device User Fee Act) Reauthorization HR 452 - Medicine Decisions Act of 2011 (IPAB) 340B Drug Discount Program HR 2245 - Drug Shortages Dual Eligibles Program HR 436, S 17 Medical Device Tax Repeal Reauthorization of Best Pharmaceuticals for Children Act (BPCA) Pediatric Research Equity Act (PREA) Drug Distribution Security (Track & Trace) HR 2672 Preserving Access to Orphan Drugs Act of 2011 S 1423 Preserving Access to Orphan Drugs Act of 2011 S. 3187 Food and Drug Administration Safety and Innovation Act Certified Importer Program S.1855, HR 2405 Pandemic and All-Hazards Preparedness Act Reauthorization of 2011
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| MARY L COEN | — |
| DAVID DRAKE | — |
| JAMES ELKIN | — |
| SARAH HALLER | — |
| BRENDA J LUCKRITZ | — |
| SHAWN O'NEAIL | — |
| KATHERINE SOLON | — |
| JENNIFER YOUNG MALONEY | — |
Budget/Appropriations BUD
HR 1458 Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009 S565 Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009 Pandemic Influenza Funding FDA Appropriations funding for Generic Drugs Certified Importer Program (CIP) HR 1 American Recovery and Reinvetment Act FY 2011 - DOD Appropriations Bill 2011 Continuing Resolutions FY 2013 - Labor HHS Appropriations Bill
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| MARY L COEN | — |
| DAVID DRAKE | — |
| JAMES ELKIN | — |
| SARAH HALLER | — |
| BRENDA J LUCKRITZ | — |
| SHAWN O'NEAIL | — |
| KATHERINE SOLON | — |
| JENNIFER YOUNG MALONEY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.